Cargando…

Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms

Thyroid cancer is the most common endocrine malignancy, and the global incidence has increased rapidly over the past few decades. Anaplastic thyroid cancer (ATC) is highly aggressive, dedifferentiated, and patients have a median survival of fewer than 6 months. Oncogenic alterations in ATC include a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Cole D, Bolf, Eric L, Gillis, Noelle E, Cozzens, Lauren M, Tomczak, Jennifer A, Carr, Frances E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271203/ https://www.ncbi.nlm.nih.gov/pubmed/34258492 http://dx.doi.org/10.1210/jendso/bvab102

Ejemplares similares

SAT-571 Restoration of Thyroid Hormone Receptor Beta Signaling Reprograms Anaplastic Thyroid Cancer Cells
por: Gillis, Noelle, et al.
Publicado: (2019)

OR21-03 Determining Novel Therapeutic Targets Using an in Vitro Model of TRb Tumor Suppression in Anaplastic Thyroid Cancer
por: Gillis, Noelle E, et al.
Publicado: (2020)

SAT-573 Characterization of the Gene Expression Program of a Mutant Thyroid Hormone Receptor in Anaplastic Thyroid Cancer
por: Bolf, Eric, et al.
Publicado: (2019)

Targeting Glycogen Metabolism as a Novel Therapeutic Approach in Anaplastic Thyroid Cancer
por: Davidson, Cole, et al.
Publicado: (2021)

Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors
por: Davidson, Cole D., et al.
Publicado: (2021)

Apatinib-induced protective autophagy and apoptosis through the AKT–mTOR pathway in anaplastic thyroid cancer
por: Feng, Haoran, et al.
Publicado: (2018)

Downregulation of AKT/mTOR signaling pathway for Salmonella-mediated autophagy in human anaplastic thyroid cancer
por: Wu, Li-Hsien, et al.
Publicado: (2022)

Thyroid hormone dependent transcriptional programming by TRβ requires SWI/SNF chromatin remodelers
por: Gillis, Noelle E, et al.
Publicado: (2022)

Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways
por: Park, Chan Ho, et al.
Publicado: (2018)

TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway
por: Jiang, Qiuli, et al.
Publicado: (2023)

miRNA-125a modulates autophagy of thyroiditis through PI3K/Akt/mTOR signaling pathway
por: Chen, Danyan, et al.
Publicado: (2019)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma
por: Gao, Haoji, et al.
Publicado: (2022)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines
por: Nozhat, Zahra, et al.
Publicado: (2018)

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2016)

Anaplastic Thyroid Carcinoma
por: Taccaliti, Augusto, et al.
Publicado: (2012)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway
por: Luo, Xue, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2018)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012)

Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Anaplastic Thyroid Carcinoma: An Update
por: Jannin, Arnaud, et al.
Publicado: (2022)

Anaplastic Thyroid Carcinoma with Gastric Metastasis
por: CHAVEZ, A.A.L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rt9f1bucdkv80ce0a75bfgsv4o